Bellevue Life Sciences Acquisition Corp. Rights
BLACR
BLACR was delisted on the 14th of February, 2025.
14 hedge funds and large institutions have $479K invested in Bellevue Life Sciences Acquisition Corp. Rights in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$89.6K |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$55.9K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$48.3K |
| 4 |
SCM
Saba Capital Management
New York
|
+$38.9K |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$36.2K |
Top Sellers
BLACR Hedge Fund Activity: Q1 2023 in Review
14 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Bellevue Life Sciences Acquisition Corp. Rights (BLACR) for Q1 2023, worth a combined $479K.
Buyers outnumbered sellers: 14 funds opened new BLACR positions and 0 closed out — a net gain of 14 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $89.6K.
- 14 institutional investors held Bellevue Life Sciences Acquisition Corp. Rights (BLACR) as of Q1 2023, up from 0 in Q4 2022.
- Funds reported $479K of Bellevue Life Sciences Acquisition Corp. Rights stock for Q1 2023.
- 14 funds opened new Bellevue Life Sciences Acquisition Corp. Rights positions in Q1 2023 and 0 closed out, a net change of +14 holders.
- The largest Bellevue Life Sciences Acquisition Corp. Rights buyer in Q1 2023 was Highbridge Capital Management, an estimated $89.6K added.
Based on aggregated 13F filings for Q1 2023.